Assenagon Asset Management S.A. Has $1.62 Million Stock Position in Codexis, Inc. (NASDAQ:CDXS)

Assenagon Asset Management S.A. grew its stake in Codexis, Inc. (NASDAQ:CDXS - Free Report) by 109.2% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 602,288 shares of the biotechnology company's stock after acquiring an additional 314,424 shares during the quarter. Assenagon Asset Management S.A. owned 0.73% of Codexis worth $1,620,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Vanguard Group Inc. increased its stake in shares of Codexis by 7.5% in the 4th quarter. Vanguard Group Inc. now owns 4,463,801 shares of the biotechnology company's stock valued at $21,292,000 after acquiring an additional 311,082 shares during the last quarter. Telemark Asset Management LLC grew its position in shares of Codexis by 11.3% in the 4th quarter. Telemark Asset Management LLC now owns 3,000,000 shares of the biotechnology company's stock valued at $14,310,000 after purchasing an additional 303,589 shares during the period. Ameriprise Financial Inc. grew its position in shares of Codexis by 0.5% in the 4th quarter. Ameriprise Financial Inc. now owns 2,399,650 shares of the biotechnology company's stock valued at $11,446,000 after purchasing an additional 12,625 shares during the period. Geode Capital Management LLC grew its position in shares of Codexis by 12.9% in the 4th quarter. Geode Capital Management LLC now owns 1,855,514 shares of the biotechnology company's stock valued at $8,853,000 after purchasing an additional 211,475 shares during the period. Finally, Nuveen Asset Management LLC grew its position in shares of Codexis by 18.6% in the 4th quarter. Nuveen Asset Management LLC now owns 1,812,345 shares of the biotechnology company's stock valued at $8,645,000 after purchasing an additional 283,760 shares during the period. 78.54% of the stock is owned by institutional investors.

Codexis Stock Down 2.6%

Shares of CDXS traded down $0.06 on Friday, hitting $2.29. The company's stock had a trading volume of 1,073,833 shares, compared to its average volume of 717,701. The company has a quick ratio of 3.64, a current ratio of 3.72 and a debt-to-equity ratio of 0.59. The firm's fifty day moving average price is $2.34 and its 200-day moving average price is $3.42. Codexis, Inc. has a fifty-two week low of $1.90 and a fifty-two week high of $6.08. The firm has a market capitalization of $189.73 million, a price-to-earnings ratio of -2.31 and a beta of 2.52.

Codexis (NASDAQ:CDXS - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.05). Codexis had a negative net margin of 149.47% and a negative return on equity of 118.47%. The business had revenue of $7.54 million during the quarter, compared to analyst estimates of $10.38 million. On average, equities research analysts expect that Codexis, Inc. will post -0.77 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen upgraded Codexis to a "sell" rating in a research report on Friday, May 16th.

About Codexis

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.